Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
Phase 3 Trials: MDMA-Assisted Therapy for PTSD
Vancouver Study Site Begins Screening in Multi-Site Open-Label Extension Study of MDMA-Assisted Therapy for PTSD (MAPPUSX)
On February 28, 2022, the thirteenth study site in our multi-site open-label extension study of MDMA-assisted therapy for PTSD (MAPPUSX) officially began screening potential study participants. This study …
TODAY Show: New Research Shows How Psychedelic Drug Can Help People With PTSD
MAPS is on The TODAY Show! This morning, NBC educated millions of people about psychedelic science by airing an interview with MAPS Founder Rick Doblin, Ph.D., and MDMA-assisted therapy study participants …
Matters Arising: MAPS’ Pivotal Phase 3 Trial Advances Scientific Discourse in Nature Medicine
The results of the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD have sparked scientific discourse: Highly statistically significant results and exceptional outcomes for people living …
A Psychedelic Drug Passes a Big Test for PTSD Treatment
Rachel Nuwer writes in the New York Times: “In an important step toward medical approval, MDMA . . . was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired …
Study: MDMA-Assisted Therapy Will Be Cost-Effective in the Treatment of PTSD
A peer-reviewed study published today in the research journal PLOS ONE demonstrates that MDMA-assisted psychotherapy is cost-effective in the treatment of posttraumatic stress disorder (PTSD). It is estimated …
Phase 3 Program: MDMA-Assisted Therapy for PTSD
A Phase 3 Program of MDMA-Assisted Therapy for the Treatment of Severe Posttraumatic Stress Disorder (PTSD) Two Trials: MAPP1 and MAPP2 Study Sponsor: MAPS, a 501(c)(3) non-profit research organization …